1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Product and Pipeline Analysis of the Global Parkinson's Disease Therapeutics Market

Rising Incidence of Disease Urges Strong Pipeline Development

Executive Summary

•An aging population contributes to the demand for Parkinson’s disease therapeutics. The available levodopa-based drugs are modestly effective.
•The drugs available or in the pipeline for Parkinson’s are only used to suppress the symptoms as there is still no cure for the disease.
•Genetic targets, namely ’LRRK2’ and ’alpha-synuclein’, offers a promising future cure for the disease.
•Low, unmet therapeutic response to overall Parkinson’s disease therapeutics corresponds to a smaller pipeline investment in comparison to Alzheimer’s disease and other central nervous system (CNS) disorders.
•Market demand for Parkinson’s disease therapeutics is largely generated for the disease modification sector to reduce the onset of symptoms from a disease-eliminating perspective.
•A limited number of available animal models for testing new Parkinson’s disease therapeutics limits the product pipeline for developing disease-eliminating drugs.
•Deep brain stimulation, a surgical procedure, is only conducted on patients suffering from severe Parkinson’s disease and patients with profound medication-induced side effects, such as debilitating dyskinesia.
•Boehringer Ingelheim, GlaxoSmilthKline (GSK), Orion Corporation, Merck & Co, UCB Pharma, and Novartis are some of the key big pharmaceutical competitors in this market.

Methodology and Scope

•This research service focusses on existing therapeutics and the product pipeline for the treatment of Parkinson’s disease using dopamine replacement therapies, dopamine agonists, Monoamine Oxidase (MAO) inhibitors, Catechol O-methyltransferase (COMT) inhibitors and other pharmacological approaches of current global interest. This research service does not cover vaccines.
•A product and pipeline assessment is provided for marketed and investigational products as well as combination regimens for Parkinson’s disease therapeutics. Segmentation by drug class is provided with supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.
•The information contained in this research service was derived from published sources including the following: disease organisation web sites; public health organisation web sites; company publications, including annual reports, SEC filings, and press releases; government public sources; and published articles in scientific journals.

Introduction

Parkinson’s disease is a chronic neurodegenerative disorder with a deceptive onset. The disease is characterised by the gradual loss of motor functions of the body due to the generation of dopamine-producing cells. Postural instability, freezing gait, and difficulty in speech and swallowing are some of the most commonly witnessed symptoms in an individual diagnosed with Parkinson’s disease.
The average incidence rate of the disease is between X and X per X people per year, as per World Health Organisation (WHO) data on Parkinson’s disease. No diagnosis for detecting the onset of the disease has been established yet. Parkinson’s disease commonly occurs to people over the age of X. Differences in the occurrence of the disease are based on environmental risk factors, and the genetic diversity of the global population, which is under the study. Caucasians in North America and Europe report a higher rate of disease prevalence in comparison to Asians in China and Japan. The lowest rate of the disease is recorded among the ethnic groups in Africa.
The disease progresses gradually, with deteriorating motor symptoms giving rise to motor fluctuations and dyskinesia.

Table Of Contents

Product and Pipeline Analysis of the Global Parkinson's Disease Therapeutics Market
Executive Summary
Mode of Drug Administration for Parkinson's Disease
Methodology and Scope
Introduction
Global Prevalence of Parkinson's Disease by Country
Global Incidence of Parkinson's Disease by Country
Market Overview
Market Overview—Segmentation by Types of Therapeutics
Market Overview—Segmentation Illustrated
Overview for Market Opportunities
Parkinson's Disease Therapeutics Market
Competitive Landscape—Marketed Products and Products in Development
Marketed Product Synopsis—Parkinson's Disease Therapeutics
Pipeline Synopsis—Parkinson's Disease Therapeutics
Parkinson's Disease Therapeutics Market—Products in Clinical Development
Parkinson's Disease Therapeutics Market—Competitive Landscape: Major Ongoing Trials
Innovations that Failed
Competitive Landscape—Projected Launch Timeline for Key Pipeline Drugs
Competitive Landscape—Company Assets by Drug Pipeline Class
Product Dashboards
Product Dashboard: Stalevo (entacapone)—Orion Corporation
Product Dashboard: Sinemet (carbidopa-levodopa)—Merck
Product Dashboard: Azilect (rasagiline) By TEVA Pharmaceuticals
Product Dashboard: Mirapex (pramipexole) By Boehringer Ingelheim
Product Dashboard: Neupro (rotigotine) By UCB Pharmaceuticals
Product Dashboard: Requip (ropinrole) By GSK
Product Dashboard: Eldepryl (Selegiline hydrochloride) By Orion Corporation
Conclusions and Recommendations
Key Companies to Watch
Legal Disclaimer
Appendix
The Frost and Sullivan Story

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Parkinson%s Disease  - Market Insights, Epidemiology and Market Forecast-2023

Parkinson%s Disease  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Parkinson’s Disease - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and ...

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • November 2016
  • by Global Data

EpiCast Report: Schizophrenia - Epidemiology Forecast to 2025 Summary Schizophrenia is a severe mental disorder that affects an individual’s behaviors, thoughts, and emotions; it is extremely heterogeneous, ...

Parkinson%s Disease  - Epidemiology Forecast To 2023

Parkinson%s Disease  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight “Parkinson's Disease  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Parkinson's Disease  in seven major markets (US, France, Germany, Italy, Spain, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.